These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15829505)

  • 1. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
    Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Bailey CD; Rogers DA; Johnson GV; Hayden MR; Leavitt BR
    J Neurochem; 2005 Oct; 95(1):210-20. PubMed ID: 16181425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
    Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR
    Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.
    Van Raamsdonk JM; Pearson J; Slow EJ; Hossain SM; Leavitt BR; Hayden MR
    J Neurosci; 2005 Apr; 25(16):4169-80. PubMed ID: 15843620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
    Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
    Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
    J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild-type huntingtin plays a role in brain development and neuronal survival.
    Reiner A; Dragatsis I; Zeitlin S; Goldowitz D
    Mol Neurobiol; 2003 Dec; 28(3):259-76. PubMed ID: 14709789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
    Pouladi MA; Xie Y; Skotte NH; Ehrnhoefer DE; Graham RK; Kim JE; Bissada N; Yang XW; Paganetti P; Friedlander RM; Leavitt BR; Hayden MR
    Hum Mol Genet; 2010 Apr; 19(8):1528-38. PubMed ID: 20097678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
    Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
    J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Lu G; Barakauskas VE; Barr AM; Honer WG; Hayden MR; Leavitt BR
    Exp Neurol; 2005 Dec; 196(2):266-72. PubMed ID: 16129433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.
    Graham RK; Deng Y; Pouladi MA; Vaid K; Ehrnhoefer D; Southwell AL; Bissada N; Franciosi S; Hayden MR
    J Huntingtons Dis; 2012; 1(2):243-60. PubMed ID: 25063333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
    Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain.
    Van Raamsdonk JM; Metzler M; Slow E; Pearson J; Schwab C; Carroll J; Graham RK; Leavitt BR; Hayden MR
    Neurobiol Dis; 2007 Apr; 26(1):189-200. PubMed ID: 17276692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.